Practices of Personal Protective Measures against SARS-Cov-2 among Undergraduate Medical Students in South India

Introduction: The use of personal protective measures holds relevance despite mass immunization coverage of COVID-19 vaccination in the population. This is because vaccination only gives protection from severe COVID-19 and does not prevent the risk of infection. Medical students can be vital in training people in infection control practices. The study aimed to assess the practices of undergraduate medical students regarding personal protective measures against COVID-19. Methods: A cross-sectional study was done among first to final-year students at a private medical college in Mangalore. Data were collected using a Microsoft form. Results: The mean age of the 302 participants was 21.2±1.6 years. The majority of them were females [179 (59.3%)]. Face mask was worn by 295(97.7%) participants. Non-recommended types of face masks like using cloth masks [108 (36.6%)] and handkerchiefs [7 (2.4%)] were reported by participants. 35 (11.9%) of them wore the face mask incorrectly. Periodicity of replacement of disposable type masks was not done every day by 181(61.4%) participants. 142(48.1%) of them did not dispose of masks whenever they became moist on every occasion. Only 79 (26.8%) always practiced proper disposal of face masks. Hand sanitizer to disinfect hands was always used by 102 (33.8%) participants. Only 42 (13.9%) participants practiced correct practice of hygiene hand wash always. Only 58 (19.2%) participants had a good level of practice. Practice level was significantly poorer among males and first-year students. Conclusion: Several gaps in preventive practices against COVID-19 were identified, particularly among males and first-year students. These issues need to be addressed among medical students in future training programs

Female genital tuberculosis: Revisited.

Female genital tuberculosis (FGTB) is caused by Mycobacterium tuberculosis (rarely Mycobacterium bovis and/or atypical mycobacteria) being usually secondary to TB of the lungs or other organs with infection reaching through haematogenous, lymphatic route or direct spread from abdominal TB. In FGTB, fallopian tubes are affected in 90 per cent women, whereas uterine endometrium is affected in 70 per cent and ovaries in about 25 per cent women. It causes menstrual dysfunction and infertility through the damage of genital organs. Some cases may be asymptomatic. Diagnosis is often made from proper history taking, meticulous clinical examination and judicious use of investigations, especially endometrial aspirate (or biopsy) and endoscopy. Treatment is through multi-drug antitubercular treatment for adequate time period (rifampicin, isoniazid, pyrazinamide, ethambutol daily for 60 days followed by rifampicin, isoniazid, ethambutol daily for 120 days). Treatment is given for 18-24 months using the second-line drugs for drug-resistant (DR) cases. With the advent of increased access to rapid diagnostics and newer drugs, the management protocol is moving towards achieving universal drug sensitivity testing and treatment with injection-free regimens containing newer drugs, especially for new and previously treated DR cases

Female genital tuberculosis: Revisited

Female genital tuberculosis (FGTB) is caused by Mycobacterium tuberculosis (rarely Mycobacterium bovis and/or atypical mycobacteria) being usually secondary to TB of the lungs or other organs with infection reaching through haematogenous, lymphatic route or direct spread from abdominal TB. In FGTB, fallopian tubes are affected in 90 per cent women, whereas uterine endometrium is affected in 70 per cent and ovaries in about 25 per cent women. It causes menstrual dysfunction and infertility through the damage of genital organs. Some cases may be asymptomatic. Diagnosis is often made from proper history taking, meticulous clinical examination and judicious use of investigations, especially endometrial aspirate (or biopsy) and endoscopy. Treatment is through multi-drug antitubercular treatment for adequate time period (rifampicin, isoniazid, pyrazinamide, ethambutol daily for 60 days followed by rifampicin, isoniazid, ethambutol daily for 120 days). Treatment is given for 18-24 months using the second-line drugs for drug-resistant (DR) cases. With the advent of increased access to rapid diagnostics and newer drugs, the management protocol is moving towards achieving universal drug sensitivity testing and treatment with injection-free regimens containing newer drugs, especially for new and previously treated DR cases

Efficacy and Safety of COVID-19 Vaccines—An Update

A few centuries ago, the first vaccine vial was formulated, and since then, they have resulted in an eminent reduction in infectious diseases associated morbidity and mortality. The discovery of the novel SARS-CoV-2 virus and the COVID-19 disease and its steady progression to a global pandemic with 603,711,760 confirmed cases and 6,484,136 reported deaths according to the World Health Organization (WHO) on 7 September 2022 was exceedingly catastrophic. This brought about an unexpected need for preventative and cost-effective measures to curb the devastating impact of the virus, followed by accelerated competition within the pharma giants to manufacture and dispense vaccines at an exponential rate. Non-pharmaceutical medications such as mandated face mask policies, the imposition of travel limitations and generalized disinfectant use were somewhat successful in mitigating the catastrophic effect, but the onus fell upon vaccination strategies and other medical interventions to counteract and subdue this international health threat. The need to ensure current and future pandemic preparedness, however, presents multiple hurdles, among which are equitable vaccine access and the rising trend of vaccine hesitancy at an individual and international level, which are beyond the scope of this discussion. With this review article, we seek to draw perspective on current COVID-19 virus variants, in-hand vaccine types with their mechanism of action along with their effectiveness and safety profile. We also aim to discuss substantial side effects while adding a segment on the booster dose controversy